المؤلفون: Santiago-O'Farrill JM, Weroha SJ, Hou X, Oberg AL, Heinzen EP, Maurer MJ, Pang L, Rask P, Amaravadi RK, Becker SE, Romero I, Rubio MJ, Matias-Guiu X, Santacana M, Llombart-Cussac A, Poveda A, Lu Z, Bast RC

المصدر: CANCER
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)

مصطلحات موضوعية: resistance, autophagy, ovarian cancer, poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors

URL الوصول: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::7167f232a7994aad292a28abc3ff2720
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=7107

المؤلفون: Santiago-O'Farrill JM; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Blessing Bollu A; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Yang H; The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Orellana V; The University of Texas MD Anderson Cancer Center, Houston, United States., Pina M; The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Zhang X; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Liu J; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Bast RC; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Lu Z; The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

المصدر: Molecular cancer research : MCR [Mol Cancer Res] 2024 May 23. Date of Electronic Publication: 2024 May 23.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101150042 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3125 (Electronic) Linking ISSN: 15417786 NLM ISO Abbreviation: Mol Cancer Res Subsets: MEDLINE

المؤلفون: Timofeeva N; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Ayres ML; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Baran N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Santiago-O'Farrill JM; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Bildik G; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Lu Z; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Konopleva M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Gandhi V; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

المصدر: Frontiers in oncology [Front Oncol] 2023 May 09; Vol. 13, pp. 1161254. Date of Electronic Publication: 2023 May 09 (Print Publication: 2023).

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE

المؤلفون: Lu Z; Department of Experimental Therapeutics., Mao W; Department of Experimental Therapeutics., Yang H; Department of Experimental Therapeutics., Santiago-O'Farrill JM; Department of Experimental Therapeutics., Rask PJ; Department of Experimental Therapeutics., Mondal J; Department of Experimental Therapeutics., Chen H; Department of Bioinformatics & Computational Biology, and., Ivan C; Department of Experimental Therapeutics.; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Liu X; Department of Experimental Therapeutics., Liu CG; Department of Experimental Therapeutics., Xi Y; Department of Bioinformatics & Computational Biology, and., Masuda K; The University of Texas MD Anderson UTHealth Graduate School of Biomedical Sciences, Houston, Texas, USA.; Ovarian Cancer Cell Laboratory, Weatherall Institute of Molecular Medicine, University of Oxford, Headington, Oxford, United Kingdom., Carrami EM; The University of Texas MD Anderson UTHealth Graduate School of Biomedical Sciences, Houston, Texas, USA.; Ovarian Cancer Cell Laboratory, Weatherall Institute of Molecular Medicine, University of Oxford, Headington, Oxford, United Kingdom., Chen M; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Tang Y; Department of Bioinformatics & Computational Biology, and.; The University of Texas MD Anderson UTHealth Graduate School of Biomedical Sciences, Houston, Texas, USA., Pang L; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Lakomy DS; Department of Experimental Therapeutics., Calin GA; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Liang H; Department of Bioinformatics & Computational Biology, and.; Department of Systems Biology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Ahmed AA; Ovarian Cancer Cell Laboratory, Weatherall Institute of Molecular Medicine, University of Oxford, Headington, Oxford, United Kingdom.; Nuffield Department of Women's & Reproductive Health, University of Oxford, Women's Centre, John Radcliffe Hospital, Oxford, United Kingdom.; Oxford NIHR Biomedical Research Centre, Oxford, United Kingdom., Vankayalapati H; Arrien Pharmaceuticals, Salt Lake City, Utah, USA., Bast RC Jr; Department of Experimental Therapeutics.

المصدر: The Journal of clinical investigation [J Clin Invest] 2022 Jun 01; Vol. 132 (11).

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 7802877 Publication Model: Print Cited Medium: Internet ISSN: 1558-8238 (Electronic) Linking ISSN: 00219738 NLM ISO Abbreviation: J Clin Invest Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents*/therapeutic use , Ovarian Neoplasms*/drug therapy , Ovarian Neoplasms*/genetics , Triple Negative Breast Neoplasms*/drug therapy , Triple Negative Breast Neoplasms*/genetics, Protein Kinase Inhibitors/*pharmacology , Protein Serine-Threonine Kinases/*antagonists & inhibitors, Female ; Humans ; Poly(ADP-ribose) Polymerase Inhibitors/pharmacology ; Recombinational DNA Repair

المؤلفون: Blessing AM; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Santiago-O'Farrill JM; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Mao W; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Pang L; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Ning J; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Pak D; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Bollu LR; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Rask P; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Iles L; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Yang H; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Tran S; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Elmir E; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Bartholomeusz G; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Langley R; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Lu Z; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Bast RC Jr; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

المصدر: Cancer [Cancer] 2020 Aug 01; Vol. 126 (15), pp. 3579-3592. Date of Electronic Publication: 2020 Jun 02.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Anaplastic Lymphoma Kinase/*genetics , Ovarian Neoplasms/*drug therapy , STAT3 Transcription Factor/*genetics , rho GTP-Binding Proteins/*genetics, Anaplastic Lymphoma Kinase/antagonists & inhibitors ; Animals ; Autophagy/drug effects ; Cell Line, Tumor ; Cell Lineage/genetics ; Cell Survival/genetics ; Crizotinib/pharmacology ; Drug Resistance, Neoplasm/genetics ; Female ; Gene Expression Regulation, Neoplastic/drug effects ; Heterografts ; Humans ; Mice ; Ovarian Neoplasms/genetics ; Ovarian Neoplasms/pathology ; Protein Kinase Inhibitors/pharmacology ; RNA, Small Interfering/genetics ; RNA, Small Interfering/pharmacology ; Signal Transduction/drug effects

المؤلفون: Santiago-O'Farrill JM; Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Kleinerman ES; Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Hollomon MG; Department of Biology, Texas Southern University, Houston, Texas, USA., Livingston A; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Wang WL; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Tsai JW; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Gordon NB; Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

المصدر: Oncotarget [Oncotarget] 2017 Aug 17; Vol. 9 (2), pp. 1602-1616. Date of Electronic Publication: 2017 Aug 17 (Print Publication: 2018).

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Impact Journals Country of Publication: United States NLM ID: 101532965 Publication Model: eCollection Cited Medium: Internet ISSN: 1949-2553 (Electronic) Linking ISSN: 19492553 NLM ISO Abbreviation: Oncotarget Subsets: PubMed not MEDLINE

المؤلفون: Zhou J; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Obstetrics and Gynecology, The First Affiliated Hospital of Soochow University, Suzhou, China., Alfraidi A; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Zhang S; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Santiago-O'Farrill JM; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Yerramreddy Reddy VK; Arrien Pharmaceuticals, Salt Lake City, Utah., Alsaadi A; The Nuffield Department of Obstetrics and Gynecology, University of Oxford, Oxford, United Kingdom., Ahmed AA; The Nuffield Department of Obstetrics and Gynecology, University of Oxford, Oxford, United Kingdom., Yang H; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Liu J; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Mao W; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Wang Y; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Takemori H; National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Ibaraki, Osaka, Japan., Vankayalapati H; Arrien Pharmaceuticals, Salt Lake City, Utah., Lu Z; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Bast RC Jr; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas. rbast@mdanderson.org.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2017 Apr 15; Vol. 23 (8), pp. 1945-1954. Date of Electronic Publication: 2016 Sep 27.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents/*pharmacology , Ovarian Neoplasms/*pathology , Protein Serine-Threonine Kinases/*antagonists & inhibitors, Animals ; Apoptosis/drug effects ; Cell Line, Tumor ; Centrosome/drug effects ; Drug Synergism ; Female ; Gene Knockdown Techniques ; Humans ; Immunohistochemistry ; Mice ; Mice, Nude ; Paclitaxel/pharmacology ; Tissue Array Analysis ; Xenograft Model Antitumor Assays

المؤلفون: Hollomon MG; Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA. hollomon_mg@tsu.edu., Gordon N, Santiago-O'Farrill JM, Kleinerman ES

المصدر: BMC cancer [BMC Cancer] 2013 Oct 26; Vol. 13, pp. 500. Date of Electronic Publication: 2013 Oct 26.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Bone Neoplasms/*genetics , Bone Neoplasms/*metabolism , Camptothecin/*toxicity , Microtubule-Associated Proteins/*genetics , Osteosarcoma/*genetics , Osteosarcoma/*metabolism , Oxidative Stress/*drug effects , Oxidative Stress/*genetics, Animals ; Antineoplastic Agents, Phytogenic/toxicity ; Autophagy/drug effects ; Autophagy/genetics ; Autophagy-Related Protein 5 ; Buthionine Sulfoximine/pharmacology ; Caspases/metabolism ; Cell Line, Tumor ; Cell Survival/drug effects ; Cell Survival/genetics ; Enzyme Activation/drug effects ; Gene Knockdown Techniques ; Membrane Potential, Mitochondrial/drug effects ; Mice ; Microtubule-Associated Proteins/metabolism

المؤلفون: Irwin ME; Department of Pediatrics Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Nelson LD, Santiago-O'Farrill JM, Knouse PD, Miller CP, Palla SL, Siwak DR, Mills GB, Estrov Z, Li S, Kornblau SM, Hughes DP, Chandra J

المصدر: PloS one [PLoS One] 2013 Aug 01; Vol. 8 (8), pp. e70608. Date of Electronic Publication: 2013 Aug 01 (Print Publication: 2013).

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: Electronic-Print Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

مواضيع طبية MeSH: Apoptosis/*drug effects , ErbB Receptors/*antagonists & inhibitors , Philadelphia Chromosome/*drug effects , Precursor Cell Lymphoblastic Leukemia-Lymphoma/*drug therapy , Precursor Cell Lymphoblastic Leukemia-Lymphoma/*pathology , Protein Kinase Inhibitors/*pharmacology , Signal Transduction/*drug effects, Adolescent ; Adult ; Aged ; Aged, 80 and over ; Caspase 3/metabolism ; Cell Proliferation/drug effects ; Enzyme Activation/drug effects ; ErbB Receptors/metabolism ; Female ; Fusion Proteins, bcr-abl/metabolism ; Gene Expression Regulation, Neoplastic/drug effects ; Humans ; Male ; Middle Aged ; Molecular Targeted Therapy ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics ; Protein Kinase Inhibitors/chemistry ; Protein Kinase Inhibitors/therapeutic use ; Young Adult